Publications
2024
Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by <i>Pseudomonas aeruginosa</i>.
Farrington, N., Dubey, V., Johnson, A., Horner, I., Stevenson, A., Unsworth, J., . . . Darlow, C. A. (2024). Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by <i>Pseudomonas aeruginosa</i>.. mBio, 15(2), e0316523. doi:10.1128/mbio.03165-23
2022
Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings
Darlow, C. A., McEntee, L., Johnson, A., Farrington, N., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(12), 3349-3357. doi:10.1093/jac/dkac323
30 Determining a potential alternative empirical antibiotic regimen for the treatment of neonatal sepsis in low- and middle-income settings using pre-clinical in vitro techniques
Darlow, C., Farrington, N., McEntee, L., Johnson, A., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). 30 Determining a potential alternative empirical antibiotic regimen for the treatment of neonatal sepsis in low- and middle-income settings using pre-clinical in vitro techniques. Clinical Infection in Practice, 15, 100191. doi:10.1016/j.clinpr.2022.100191
Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance
Darlow, C. A., Farrington, N., Johnson, A., McEntee, L., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(5), 1334-1343. doi:10.1093/jac/dkac038
Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance
Farrington, N., McEntee, L., Johnson, A., Unsworth, J., Darlow, C., Jimenez-Valverde, A., . . . Hope, W. (2022). Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 66(4). doi:10.1128/aac.02181-21
2021
Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.
Darlow, C. A., Docobo-Perez, F., Farrington, N., Johnson, A., McEntee, L., Unsworth, J., . . . Hope, W. (2021). Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.. Antimicrobial Agents and Chemotherapy. doi:10.1128/aac.00293-21
2020
Pharmacodynamics of the Novel Metallo-beta-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae
Das, S., Johnson, A., McEntee, L., Farrington, N., Kirby, A., Unsworth, J., . . . Hope, W. (2020). Pharmacodynamics of the Novel Metallo-beta-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 64(11). doi:10.1128/AAC.01076-20
Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.
Das, S., Johnson, A., McEntee, L., Farrington, N., Kirby, A., Unsworth, J., . . . Hope, W. (2020). Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.. Antimicrob Agents Chemother, 64(11). doi:10.1128/AAC.01076-20
Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i>
Johnson, A., McEntee, L., Farrington, N., Kolamunnage-Dona, R., Franzoni, S., Vezzelli, A., . . . Hope, W. (2020). Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(6). doi:10.1128/AAC.00180-20
2019
Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.
Hope, W., Stone, N. R. H., Johnson, A., McEntee, L., Farrington, N., Santoro-Castelazo, A., . . . Bicanic, T. (2019). Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.. mBio, 10(6). doi:10.1128/mbio.02575-19
Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections
McEntee, L., Johnson, A., Farrington, N., Unsworth, J., Dane, A., Jain, A., . . . Hope, W. (2019). Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(8). doi:10.1128/AAC.00603-19
2018
Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease
Nixon, G. L., McEntee, L., Johnson, A., Farrington, N., Whalley, S., Livermore, J., . . . Hope, W. (2018). Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease. Antimicrobial Agents and Chemotherapy, 62(4), e01909-e01917. doi:10.1128/aac.01909-17
2017
Pharmacodynamics of teicoplanin against MRSA
Ramos-Martin, V., Johnson, A., McEntee, L., Farrington, N., Padmore, K., Cojutti, P., . . . Hope, W. W. (2017). Pharmacodynamics of teicoplanin against MRSA. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(12), 3382-3389. doi:10.1093/jac/dkx289
Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease.
Hope, W. W., McEntee, L., Livermore, J., Whalley, S., Johnson, A., Farrington, N., . . . Rex, J. H. (n.d.). Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease.. mBio, 8(4). doi:10.1128/mbio.01157-17